The Medial Temporal Atrophy (MTA) score is a measurement of brain shrinkage in the hippocampus and surrounding structures of the temporal lobe, calculated from an MRI scan and rated on a 0-4 scale called the Scheltens Scale. For families navigating a dementia diagnosis, this score translates the abstract idea of “brain changes” into a concrete number that doctors use to confirm Alzheimer’s disease and predict how quickly the condition will advance.
An MTA score of 2 or higher in someone under 75 years old (or 3 or higher in someone 75 and older) is considered abnormal and consistent with brain atrophy typical of Alzheimer’s. When your parent or spouse receives an MTA score along with their diagnosis, it answers a question many families have: is their memory loss real, or is it depression, medication side effects, or normal aging? A visible atrophy score confirms that actual structural changes in the brain are causing their symptoms—not a psychological problem or something reversible. The score also becomes a baseline for tracking whether the atrophy is stable or worsening over time, which directly influences decisions about medication, care intensity, and life planning.
Table of Contents
- How Is Medial Temporal Atrophy Measured and Scored?
- Understanding MTA Scores and What They Mean for Your Family
- Why MTA Matters for Alzheimer’s Diagnosis
- What an MTA Score Means for Care Planning and Medication Decisions
- Important Limitations: What MTA Cannot Tell You
- New Technology: AI and Automated MTA Scoring
- Serial Scanning and Monitoring Atrophy Over Time
How Is Medial Temporal Atrophy Measured and Scored?
MTA is measured from a structural MRI scan (the machine that creates detailed 3D images of the brain without radiation). A radiologist examines the MRI images and visually estimates the size of the hippocampus—a seahorse-shaped structure critical for memory formation—and the surrounding temporal lobe tissue. They rate this shrinkage on the Scheltens Scale, a 0-4 scoring system that has been the standard in neurology for over 20 years. A score of 0 means no atrophy; a score of 1 means minimal age-appropriate atrophy; scores of 2 and above indicate progressive shrinkage that exceeds normal aging. The measurement is subjective, which is why it matters which radiologist reads the scan—different specialists might rate the same brain slightly differently.
However, modern advances now include AI and deep learning algorithms that can automatically score MTA with high consistency, reducing both the time radiologists spend on each scan and the variability between different readers. This automation is improving diagnostic reliability, especially in busy hospital settings where radiologists may review hundreds of scans per week. The Scheltens Scale remains the most widely used scoring method globally because it is simple, reproducible, and strongly linked to cognitive decline. However, some newer research centers now use automated volumetric methods that measure the exact millimeter size of the hippocampus in cubic centimeters, which can detect even smaller changes over time. For most families in standard clinical settings, though, the visual 0-4 rating is what will appear on your scan report.
Understanding MTA Scores and What They Mean for Your Family
An MTA score between 0 and 1 is considered normal for your age group and does not suggest Alzheimer’s disease. A score of 2 or higher in adults under 75 years old, or a score of 3 or higher in adults 75 and older, is flagged as abnormal and is associated with Alzheimer’s pathology. This age-based cutoff exists because the brain naturally shrinks slightly with age—what is abnormal shrinkage in a 60-year-old is more expected in an 85-year-old. The clinical significance is substantial: research shows that MTA scores have 91% sensitivity and 94% specificity for diagnosing Alzheimer’s disease, meaning the scan correctly identifies the disease in 91% of people who have it and correctly rules it out in 94% of people who do not. The individual score also predicts progression speed.
Someone with an MTA score of 2 or 3 typically shows a 2.8% to 4.0% annual increase in cognitive decline, depending on disease stage, meaning their memory loss will worsen at a measurable and predictable rate. This is not a guarantee—some people progress faster, others slower—but it gives doctors and families a framework for planning. A higher score (3 or 4) usually indicates more advanced disease and faster expected decline than a score of 2. However, MTA scoring has a key limitation: the score itself does not tell you how far the atrophy has progressed or how much time remains. Two people with identical MTA scores of 3 may have very different disease timelines depending on their age, genetics, cardiovascular health, and other factors.
Why MTA Matters for Alzheimer’s Diagnosis
For decades, Alzheimer’s could only be definitively diagnosed by examining brain tissue after death. Today, structural brain imaging like MTA scoring has become one of the most reliable tools for diagnosing the disease in living patients, allowing doctors to intervene earlier with medications like lecanemab and aducanumab, which can slow cognitive decline if started in early stages. An MTA score of 2 or higher, combined with cognitive testing results and often a PET scan or cerebrospinal fluid test, creates a diagnostic picture robust enough for both research and clinical treatment.
The score directly correlates with the severity of cognitive decline that a person is experiencing. A study might show that someone with an MTA score of 2 has mild cognitive impairment, while someone with a score of 4 has moderate to severe dementia. This connection between the visible structural change and the reported memory problems reassures families that the diagnosis is grounded in biology, not subjective report. It also explains why someone with “only” an MTA score of 1 might still have memory problems—they may have Lewy body dementia, frontotemporal dementia, or another non-Alzheimer’s condition that damages different brain regions, or their memory loss may stem from depression or medication effects rather than neurodegeneration.
What an MTA Score Means for Care Planning and Medication Decisions
When doctors prescribe disease-modifying Alzheimer’s medications, they often use the MTA score as part of the evidence to decide whether treatment is appropriate. For example, newer monoclonal antibodies that target amyloid (the sticky protein that accumulates in Alzheimer’s brains) work best in people with mild cognitive impairment or early dementia—typically those with MTA scores of 2 or 3 rather than advanced scores of 4. If your family member has an MTA score of 4 with severe dementia, these medications may offer less benefit and carry greater side effects than for someone earlier in the disease. The score thus becomes a concrete data point in conversations with your neurologist about which treatments make sense and when.
An MTA score also informs care intensity and safety planning. Someone with a score of 4 (severe atrophy) may progress faster and need earlier transition to assisted living or memory care than someone with a score of 2. Families can use this information to have advance conversations about future care preferences, finances, and legal documents like powers of attorney before cognitive decline makes those discussions impossible. The tradeoff, however, is that fixating on a single MTA score can feel reductive—the number does not capture personality changes, behavioral symptoms, or the emotional toll of the disease, all of which matter as much as the neuroimaging for quality-of-life planning.
Important Limitations: What MTA Cannot Tell You
MTA scoring is not the same as a complete diagnosis, and it should not be interpreted in isolation. A high MTA score confirms that atrophy is present, but the score alone cannot tell you whether someone is in early, middle, or late-stage disease; whether their decline will be slow or rapid; or how many years they have before severe impairment occurs. Two people with identical MTA scores can have dramatically different disease courses based on their education level (cognitive reserve), cardiovascular fitness, social engagement, genetics, and the presence of other brain pathologies like small vessel disease or Lewy bodies mixed in with Alzheimer’s changes. Another critical limitation: an MTA score is a snapshot from a single day, not a trend.
Doctors use serial MRI scans (repeated scans over months or years) to see whether atrophy is stable or accelerating, but a single scan tells you only the current state. Additionally, not all memory loss or cognitive decline is caused by atrophy that an MTA score would capture. Some people have cognitive symptoms driven primarily by amyloid and tau pathology in the brain without significant visible atrophy on MRI; others have cognitive decline from stroke-related changes, Lewy body accumulation, or frontotemporal dementia that affects different brain regions than the hippocampus. If someone has cognitive symptoms but a normal or only mildly elevated MTA score, further diagnostic testing (PET imaging, blood biomarkers for amyloid and tau, or neuropsychological testing) may be needed to clarify the underlying cause.
New Technology: AI and Automated MTA Scoring
Recent advances in artificial intelligence are transforming how MTA scores are calculated. Rather than relying on a radiologist’s visual estimate, deep learning algorithms can now automatically segment the hippocampus from an MRI scan and measure its volume with precision to the millimeter. These automated systems have been trained on thousands of scans and can score atrophy faster and more consistently than manual rating. A radiologist can now review an automated MTA score in seconds rather than spending minutes on visual assessment, which speeds up diagnostic workflows and reduces the chance of inter-observer variation (disagreement between different radiologists on the same scan).
AI-based MTA scoring is also enabling better research. Studies that previously would have required a radiologist to manually rate thousands of scans can now process those scans in hours, allowing researchers to identify new patterns and associations. For example, recent research has discovered links between high MTA scores and small vessel disease (stroke-related damage to tiny blood vessels in the brain), suggesting that the combination of atrophy plus vascular damage may predict even faster cognitive decline than either alone. As these tools become standard in hospital systems, families may see faster turnaround on scan reports and more precise measurement of changes over time.
Serial Scanning and Monitoring Atrophy Over Time
The most informative use of MTA scoring is not a single scan but a series of scans over time, allowing doctors to track whether the atrophy is stable or worsening. Someone who has an MTA score of 2 today and a score of 2 again one year later shows stable disease; someone whose score progresses from 2 to 3 in that same year shows accelerating atrophy and worsening prognosis. Serial scanning is particularly valuable for people starting new Alzheimer’s medications, because the goal of these drugs is to slow or halt the rate of cognitive decline, which would theoretically show up as slower progression of atrophy on follow-up MRI scans.
However, detecting meaningful change on MTA scans requires careful protocol adherence. The MRI machine, imaging parameters, radiologist, and timing of scans should be kept as consistent as possible so that any score difference truly reflects disease progression and not variation in how the scan was acquired or read. A study might show a 0.5-point change in MTA score over a year, but if the scan was done on a different machine or at a different phase of disease (e.g., during a period of illness or medication change), that change may reflect scanning variation rather than true progression. For this reason, many specialized dementia centers now use automated volumetric methods for serial scanning, which remove subjective judgment and allow detection of even small volume changes over time.
